Extensively Hydrolysed Infant Formula With Reduced Protein and MCT
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing extensively hydrolyzed infant formulas (eHFs) contain higher protein levels that may lead to weight gain and obesity risks in infants with cow's milk protein allergy, while current hypoallergenic formulas do not adequately address the need for reduced protein content without compromising growth and tolerance.
Innovation Solution
An eHF with a protein content of 2.4 g or less per 100 kcal, comprising 30% or less medium chain triglycerides (MCTs) and primarily whey protein, with at least 95% of peptides under 1200 Da, and optionally supplemented with 2′-fucosyllactose and lacto-N-neotetraose to support growth and tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If eHF contains higher protein levels (2.6-2.8 g per 100 kcal), then it covers the nutritional needs of infants with CMPA, but it increases the risk of weight gain and obesity
Solution Approach 1:
The patent applies parameter changes by reducing the protein content from the conventional 2.6-2.8 g per 100 kcal to 2.4 g or less per 100 kcal. This quantitative parameter modification allows the formula to meet the nutritional needs of infants with CMPA while simultaneously reducing the risk of weight gain and obesity, directly resolving the technical contradiction between protein sufficiency and obesity prevention.
2Object-affected harmful factors
If eHF is formulated with reduced protein content (2.4 g or less per 100 kcal), then obesity risk is diminished, but growth and development support may be compromised
Solution Approach 1:
The patent modifies the protein content parameter to 2.4 g or less per 100 kcal while compensating for potential growth deficiencies through optimized fat composition (30% or less MCT) and the inclusion of human milk oligosaccharides. This multi-parameter optimization ensures that reduced protein intake does not compromise growth support, maintaining reliability while reducing obesity risk.
3Object-affected harmful factors
If eHF contains 30% or less MCT, then adipogenic activity is reduced, but energy density may be affected
Solution Approach 1:
The patent applies parameter changes by limiting MCT content to 30% or less of total fat while adjusting the overall fat composition and quantity to maintain adequate energy density. This optimization reduces adipogenic activity associated with high MCT intake while ensuring the formula provides sufficient energy for infant growth and development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The eHF supports appropriate growth and development of allergic infants, is well-tolerated, and reduces the risk of obesity, while maintaining nutritional adequacy and safety.
Implementation Method 1
extensively hydrolysed infant formulas (eHFs) comprising a reduced amount of protein
Data Source
AI summary
An extensively hydrolysed infant formula (eHF) comprising protein, carbohydrate and fat, wherein the eHF comprises about 2.4 g or less protein per 100 kcal, wherein about 30% or less by weight of the fat is medium chain triglycerides (MCTs), and wherein the eHF may further comprise 2′-fucosyllactose (2′FL) and/or lacto-N-neotetraose (LNnT).